Secondary analysis reports no significant effect of denosumab on bone preservation in hip arthroplasty, suggesting further exploration needed.
At 5 years, the adjusted between-group difference and its 95% confidence interval showed no statistically or clinically relevant effect of denosumab. Whether longer treatment duration or a sequential post-denosumab regimen could influence long-term periprosthetic bone preservation is unknown.
No takes yet. Share an insight, caveat, or question.
Sköld et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: